Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial

Summary Background Purpose of this phase Ib trial was to establish the maximum tolerable dose (MTD) of capecitabine and to escalate the dosages of erlotinib and bevacizumab to determine the recommended phase II dose (RP2D) in patients with advanced/metastatic pancreatic adenocarcinoma not pretreated...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2019-02, Vol.37 (1), p.127-138
Hauptverfasser:	Dittrich, Christian, Königsberg, Robert, Mittlböck, Martina, Geissler, Klaus, Sahmanovic-Hrgovcic, Azra, Pleiner-Duxneuner, Johannes, Czejka, Martin, Buchner, Philipp
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Bevacizumab - administration & dosage Cancer Capecitabine - administration & dosage Cohort Studies Drug dosages Drug interaction Drug interactions Erlotinib Hydrochloride - administration & dosage Female Follow-Up Studies Hematology Humans Immunomagnetic separation Immunotherapy Inhibitor drugs Male Maximum Tolerated Dose Medicine Medicine & Public Health Metabolites Metastases Metastasis Middle Aged Monoclonal antibodies Oncology Pancreas Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Patients Pharmacokinetics Pharmacology Pharmacology/Toxicology Phase I Studies Studies Survival Rate Targeted cancer therapy Tissue Distribution Toxicity Treatment Outcome Tumor cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!